Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity [Seeking Alpha]
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: Seeking Alpha
SummarySoligenix announced positive preliminary results from its phase 3 study using SGX301 to treat patients with cutaneous T-cell lymphoma.With 8-week preliminary data released, another catalyst opportunity is at play because 12-week data from the phase 3 study is anticipated to be released June of 2020.The goal is to submit an NDA for SGX301 for the treatment of cutaneous T-cell lymphoma and then work eventually submitting an application for potential approval in the European Union.Soligenix had $5.4 million in cash as of December 31, 2019, it expects this to be enough cash to fund its operations for 12 months from March 30, 2020.Soligenix (SNGXPhase 3 Study Achieves Positive Preliminary DataThe first program to go over involves the use of SGX301 for the treatment of patients with cutaneous T-cell lymphoma.CTCL is a rare type of non-Hodgkin lymphoma (NHL))Non-Hodgkin lymphomaMycosis fungoidesBeing that CTCL is a rare type of NHL, it is not going to produce massive revenues. That's
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… [Yahoo! Finance]Yahoo! Finance
- Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaPR Newswire
- EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer [Yahoo! Finance]Yahoo! Finance
- HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment [Yahoo! Finance]Yahoo! Finance
- HyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentPR Newswire
SNGX
Sec Filings
- 12/13/24 - Form 4
- 12/13/24 - Form 4
- 12/13/24 - Form 4
- SNGX's page on the SEC website